Department of Internal Medicine, Gastroenterology, and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Hepatol Res. 2007 Sep;37 Suppl 2:S95-S100. doi: 10.1111/j.1872-034X.2007.00169.x.
Primary liver cancer, 95% of which is hepatocellular carcinoma (HCC), has ranked third in men and fifth in women as a cause of death from malignant neoplasm in Japan. Although the number of deaths and death rates from HCC increased until 2002 in Japan, annual deaths (34 089) and the death rate (27.0/100 000) from liver cancer decreased in 2003. Hepatitis C virus (HCV)-related HCC represents 75% of all HCC in Japan. The incidence of HCC without hepatitis B surface antigen (HBsAg) or anti-HCV accounted for 7-12% of HCC in Japan andhalf of non-B non-C-HCC was of unknown origin. Geographically, HCC is more frequent in western than eastern Japan, and the death rates from HCC in each prefecture correlate with the prevalence of anti-HCV, but not with HBsAg prevalence. Interferon therapy for chronic hepatitis C has reduced the risk factors for development of HCC, especially among patients with sustained response.
原发性肝癌，其中 95%为肝细胞癌（HCC），在日本已成为男性因恶性肿瘤死亡的第三大原因，女性因恶性肿瘤死亡的第五大原因。尽管日本 HCC 的死亡人数和死亡率在 2002 年之前一直在增加，但 2003 年肝癌的年死亡人数（34089 人）和死亡率（27.0/100000）有所下降。在日本，丙型肝炎病毒（HCV）相关 HCC 占所有 HCC 的 75%。无乙型肝炎表面抗原（HBsAg）或抗-HCV 的 HCC 发病率占日本 HCC 的 7-12%，一半以上的非乙型非丙型 HCC 来源不明。从地域上看，日本西部 HCC 比东部更常见，每个县的 HCC 死亡率与抗-HCV 的流行程度相关，但与 HBsAg 的流行程度无关。慢性丙型肝炎的干扰素治疗降低了 HCC 的发展风险因素，尤其是在持续应答的患者中。
